02696 HENLIUS
- 17.980
- -0.220-1.21%
HENLIUS News
Qatar Investment Authority sold 80,700 H shares of Fuhong Hanlin (02696.HK) worth about HK$1.391,300
On May 17, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 17, Qatar Investment Authority sold $80,700 H shares of $Fuhong Hanlin (02696.HK) at an average price of HK$17.24 per share on May 9, worth about HK$1,391,300. After the sale, the latest number of shares held by the Qatar Investment Authority was 13.055,900 shares, and the good position ratio dropped from 8.04% to 7.99%. Photo source: Stock Exchange's equity disclosure what is equity share
Fu Hong Han Lin (2696.HK): The turnover reached a record high, targeting the 100 billion market, and differentiated innovation showed results
Just like that, when the tide is gone, you'll know who's swimming naked. At a time when the cold wave of capital still looms over the pharmaceutical sector, there are already excellent innovative pharmaceutical companies that have taken the lead and embarked on a new journey. According to WIND data, after experiencing the first full profit in the 2023 financial report and an impressive report that continued to improve in the 2024 quarterly report, Fuhong Hanlin also ushered in a “Xiaoyangchun” in the capital market. By the close of trading on May 14, the biggest increase in the company's stock price range since October 2023 reached 91.04%. The trading volume was a record high in the company's 2 years, reaching 1,585,600 shares, and the total transaction volume reached 2,830.
Fu Hong Han Lin (02696): It is not easy for “Chinese” single antibiotics to be approved in the US. We expect Han Quyou's market share to increase further
Fu Hong Han Lin (02696): Looking forward to a further increase in Han Quyou's market share.
China Approves Clinical Trials For Breast Cancer Drugs
China's medical products administrator approved Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) unit Shanghai Henlius Biotechnology's clinical trials for HLX78 lasofoxifene tablets for br
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Shanghai Henlius Biotech Gets Go-Ahead for Clinical Trials of Breast Cancer Drug in China
Shanghai Henlius Biotech's (HKG:2696) has received approval from the National Medical Products Administration of China to begin two clinical trials of HLX78 in mainland China, a Tuesday filing on the
Fosun Pharmaceutical (600196.SH): HLX78 approved for drug clinical trials
Gelonghui, May 14, 丨 Fosun Pharmaceutical (600196.SH) announced that the company's holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary (hereinafter collectively referred to as “Fuhong Hanlin”) recently received approval from the State Drug Administration to conduct HLX78 (i.e. lasofoxifene tablets, hereinafter referred to as “the new drug”) in China (excluding Hong Kong, Macao and Taiwan regions, the same below): 1. Phase I clinical trials on healthy subjects; 2. International multi-center phase III clinical trials, indications for the new drug: Accepted in combination with abecilil
Fu Hong Han Lin (02696.HK): Clinical trial application for HLX78 (lasoxifen tablets) approved by the State Drug Administration
Gelonghui, May 14 | Fu Hong Han Lin (02696.HK) issued an announcement. Recently, HLX78 (lasoxifene tablets, lasofoxifene) (“HLX78”) was approved by the State Drug Administration to be carried out in China (excluding Hong Kong, Macao and Taiwan regions, the same below): (1) a phase 1 clinical trial in healthy Chinese subjects; and (2) an international multi-center phase 3 clinical trial. The indications are HLX78 combined with abecilil treated with aromatase inhibitors (AI) combined with cyclic kinase (CD) K4/ 6) Issued during treatment with inhibitors
Approved for the first time in the US! Fuhong Hanlin Biopharmaceutical's overseas expansion to accelerate PD-1 may become the key to overseas revenue generation
① Recently, the trutuzumab biosimilar drug (Han Quyou) independently developed by Fuhong Hanlin passed FDA approval for commercialization in the US, marking a zero breakthrough in the company's entry into the US market. ② Up to now, the share of overseas sales revenue in Fuhong Hanlin's revenue is still relatively low.
Zhu Jun, CEO of Fuhong Hanlin: Biosimilars contribute to stable cash flow, and rely on innovative drugs to rise above the ceiling
“What biosimilar drugs provide me is a stable cash flow. Each product can provide 1 billion dollars in sales every year. After we have this portion of money, we turn around to make innovative drugs with slightly higher risks, such as developing indications for Hans-like bowel cancer. Other people are afraid to do it; I dare to do it.” Zhu Jun said.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Changes in Hong Kong stocks | Fu Hong Hanlin (02696) rose more than 5%, HLX22's international multi-center phase III clinical trial approved in the US
Fu Hong Hanlin (02696) rose more than 5%. As of press release, it had risen 5.42% to HK$17.52, with a turnover of HK$3,019,300.
Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy
Shanghai Henlius Biotech's (HKG:2696) application for the phase 3 clinical trial of HLX22 in combination with Trastuzumab and chemotherapy has been approved by the United States Food and Drug Administ
Fosun Pharmaceutical (600196.SH): The holding subsidiary was approved for clinical trials of drugs by the US FDA
Gelonghui, May 6, 丨 Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary (hereinafter collectively referred to as “Fuhong Hanlin”) recently received a letter from the US FDA (i.e. the US Food and Drug Administration) agreeing to conduct clinical trials with HLX22 (i.e. anti-human epidermal growth factor receptor-2 (HER2) humanized monoclonal antibody injection) combined with trastuzumab and chemotherapy on the first-line treatment of advanced HER2 positive gastric cancer (hereinafter referred to as “this treatment plan”). Fu Hong Hanlin plans to launch this treatment in the US after conditions are met
Fu Hong Han Lin (02696.HK): The application for a phase 3 clinical trial of HLX22 combined with trastuzumab and first-line chemotherapy to treat advanced HER2-positive gastric cancer was approved by the US FDA
Gelonghui, May 6, 丨 Fu Hong Han Lin (02696.HK) announced that recently, HLX22 (anti-human epidermal growth factor receptor-2 (HER2) humanized monoclonal antibody injection) (“HLX22”) combined with trastuzumab and chemotherapy for first-line treatment of advanced HER2-positive gastric cancer was approved by the US Food and Drug Administration (FDA). According to reports, HLx22 is a novel monoclonal antibody targeting HER2, which was introduced by the company with permission from ABClon, Inc., and subsequently independently developed. Potential indications include solid tumors such as stomach cancer and breast cancer. It is already in China
Henlius Trastuzumab Erhält FDA-Zulassung in Den Vereinigten Staaten
SCHANGHAI, 6. Mai 2024 /PRNewswire/ -- Henlius Biotech, Inc. (2696.HK) gab bekannt, dass der Geschäftspartner des Unternehmens, Accord BioPharma Inc. (die US-Spezialitätenabteilung von Intas Pharma
Henlius Trastuzumab Reçoit L'approbation De La FDA Aux États-Unis
SHANGHAI, 6 mai 2024 /PRNewswire/ -- Henlius Biotech, Inc. (2696.HK) a annoncé que le partenaire commercial de la société, Accord BioPharma Inc. (la division spécialisée américaine d'Intas Phar
HENLIUS BIOTECH(2696.HK):STRONG PRODUCT SALES IN 1Q
Strong sales maintained in 1Q24. Henlius Biotech (Henlius) recorded total revenu
Henlius Biotech Logs 1.35 Billion Yuan Revenue in Q1
Shanghai Henlius Biotech (HKG:2696) recorded an operating income of about 1.35 billion yuan for the first quarter of the year, according to the company's filing on the Hong Kong Stock Exchange. Two of
Henlius Trastuzumab Receives FDA Approval in the United States
Henlius Biotech, Inc. (2696.HK) announced that the company's business partner, Accord BioPharma Inc. (the U.S. specialty division of Intas...
Analysis
Price Target
No Data
